Supercharge Your Innovation With Domain-Expert AI Agents!
Adenine single-base editing product without PAM limitation, method and application
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A single-base, gene-editing technology, applied in the fields of genetic engineering and protein modification, can solve problems such as editing efficiency limitations and achieve good application prospects
Pending Publication Date: 2022-05-31
EAST CHINA NORMAL UNIV +1
View PDF0 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although the corresponding mutation on the complementary strand of the mutation site is theoretically repairable by ABE (G>A), since the region on the complementary strand including the mutation site (G>A) is not suitable for ABE7. PAM, coupled with the limitation of ABE7.10 editing efficiency in hematopoietic stem / progenitor cells, has been unable to achieve effective repair of this pathogenic mutation by single base editing
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0072] Example 1. Guided by NGG PAM sgRNA and non-NGG PAM sgRNA respectively in healthy human hematopoietic stem / progenitor cells to achieve efficient introduction of A>G substitution at the target site (taking the electroporation delivery method as an example)
[0073] The healthy human hematopoietic stem / progenitor cells used in this example come from the peripheral blood of healthy people.
[0074] 1. Design of sgRNA
[0075] Design a non-NGG PAM sgRNA at the NACT-2 site in the intergenic region of the normal site, numbered sgNACT-2 (PAM is GGCT), and its targeting sequence is:
[0076] sgNACT-2: (SEQ ID No. 5);
[0077] Design an NGG PAM sgRNA in the normal site BCL11A gene enhancer region, numbered sg1620 (PAM is GGG), and its targeting sequence is:
[0078] sg1620: (SEQ ID No. 6);
[0079] Among them, the above two target sequences are both 20bp in length, and A in the ABE-SPRY editing window is located at the bold horizontal line mark in the above sequence.
[0...
Embodiment 2
[0109] Example 2. Repair of disease-causing sites in β-thalassemia IVS2-654 C>T-deficient hematopoietic stem / progenitor cells (taking electroporation as an example)
[0110] The β-thalassemia IVS2-654 C>T-deficient hematopoietic stem / progenitor cells used in this example came from patients heterozygous for β-thalassemia IVS2-654.
[0111] 1. Design of sgRNA
[0112] Design non-NGG PAM sgRNAs within 20 bp including the abnormal splicing mutation IVS2-654 C>T site, numbered IVS2-654-sg1 to IVS2-654-sg5, and the target sequences are:
[0113] IVS2-654-sg1: (SEQ ID No.7, PAM is TCA);
[0114] IVS2-654-sg2: (SEQ ID No.8, PAM is ATC);
[0115] IVS2-654-sg3: (SEQ ID No.9, PAM is TAT);
[0116] IVS2-654-sg4: (SEQ ID No.10, PAM is TTA);
[0117] IVS2-654-sg5: (SEQ ID No.11, PAM is ATT);
[0118] Among them, the above five targeting sequences are all 20bp in length, and the IVS2-654 C>T mutation site (the complementary strand is A, located at the bold horizontal line mark...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a PAM limitation-free adenine single base editing product, a PAM limitation-free adenine single base editing method and an application of the PAM limitation-free adenine single base editing product. The product comprises a fusion protein, the fusion protein comprises the following two parts: adenine nucleoside deaminase and endonuclease, the amino acid sequence of the adenine nucleoside deaminase comprises a sequence as shown in SEQ ID No.1, and the amino acid sequence of the endonuclease comprises a sequence as shown in SEQ ID No.2. The product can realize the introduction of Agt without PAM limitation into the genes of cells, especially hematopoietic stem / progenitor cells; g, replacement editing is carried out, the edited autologous hematopoietic stem cells of the patient are transfused back, and the purpose of thoroughly curing diseases in a long-acting mode can be achieved. The product is applied to repair of beta-thalassemia (thalassemia) related mutation IVS2-654 Cgt; the beta-globingene editing efficiency is high, the expression level of the beta-globingene can be remarkably and effectively improved, and the beta-globingene editing method has the application potential in clinical treatment of beta-anemia.
Description
technical field [0001] The present invention relates to the technical field of genetic engineering and protein transformation, in particular to a product, method and application of adenine single base editing without PAM restriction. Background technique [0002] The CRISPR / Cas9 gene editing system can cut at a specific part of DNA to generate a DNA double-strand break (DSB), and there are two repair mechanisms in the cell, non-homologous end joining and homologous recombination repair, so as to realize genome editing. But the original CRISPR technology involves DNA double-strand breaks, which pose potential risks. The development of a single-base gene editing system can achieve precise modification of specific genetic loci without causing DNA double-strand breaks. The base editor in the single-base gene editing system is mainly composed of two parts: Cas protein and DNA modificationenzyme. So far, two types of base editors have been developed: cytosine base editor (CBE),...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More